Galmed Pharmaceuticals (GLMD) Asset Writedowns and Impairment (2022 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Asset Writedowns and Impairment of $2.5 million for Q4 2025, up 118.79% year-over-year from $1.1 million in Q4 2024, and up 62675.0% quarter-over-quarter from -$4000.0 in Q3 2025.
Galmed Pharmaceuticals (GLMD) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment rose 118.79% year-over-year to $2.5 million; the TTM figure through Dec 2025 stood at $3.6 million (up 218.17% YoY), while the FY2025 annual figure was $2.5 million, up 118.34% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $2.5 million, up from -$4000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $2.5 million in Q4 2025, with the low at -$200000.0 in Q3 2022.
- The 4-year median for Asset Writedowns and Impairment is -$1500.0 (2024), against an average of $340900.0.
- The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 140.0% in 2023, then plunged 75.0% in 2024.
- Galmed Pharmaceuticals' Asset Writedowns and Impairment stood at -$200000.0 in 2022, then jumped by 104.5% to $9000.0 in 2023, then jumped by 12611.11% to $1.1 million in 2024, then jumped by 118.79% to $2.5 million in 2025.
- Business Quant data shows GLMD's Asset Writedowns and Impairment at $2.5 million in Q4 2025, -$4000.0 in Q3 2025, and $1.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | -4,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Dec 31, 2024 | 1.14 Mn |
| Dec 31, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Sep 30, 2022 | -200,000.00 |
| Sep 30, 2022 | -200,000.00 |
| Jun 30, 2022 | -32,000.00 |
| Jun 30, 2022 | -32,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Mar 31, 2022 | -10,000.00 |